ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is BrightPath Biotherapeutics Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of -36.90% over the last 5 years
3
Flat results in Jun 25
- CASH AND EQV(HY) Lowest at JPY 1,711.45 MM
- DEBT-EQUITY RATIO (HY) Highest at -85.67 %
4
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 10.42%, its profits have risen by 1%
5
Underperformed the market in the last 1 year
- The stock has generated a return of 10.42% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 29.35%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is BrightPath Biotherapeutics Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
BrightPath Biotherapeutics Co., Ltd.
2.0%
-0.14
106.96%
Japan Nikkei 225
28.54%
1.14
25.81%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-36.90%
EBIT Growth (5y)
6.42%
EBIT to Interest (avg)
-1,564.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.71
EV to EBIT
-2.28
EV to EBITDA
-2.28
EV to Capital Employed
18.95
EV to Sales
2334.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-832.10%
ROE (Latest)
-124.30%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
NET SALES(HY)
At JPY 1.08 MM has Grown at 3,163.64%
NET PROFIT(HY)
Higher at JPY -577.34 MM
RAW MATERIAL COST(Y)
Fallen by -1.03% (YoY
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at JPY 1,711.45 MM
DEBT-EQUITY RATIO
(HY)
Highest at -85.67 %
Here's what is working for BrightPath Biotherapeutics Co., Ltd.
Net Sales
At JPY 1.08 MM has Grown at 3,163.64%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (JPY MM)
Net Profit
Higher at JPY -577.34 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (JPY MM)
Raw Material Cost
Fallen by -1.03% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for BrightPath Biotherapeutics Co., Ltd.
Cash and Eqv
Lowest at JPY 1,711.45 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -85.67 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
